Segment Information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Information

13. Segment Information

The CODM assesses performance for the life sciences segment based on net loss, which includes evaluating the progress of ongoing clinical trials. The life sciences segment is dedicated to developing off-the-shelf, allogeneic, NK cell-based therapies that are effective, safe and accessible for patients with devastating autoimmune diseases and cancers. The measure of segment assets is reported on the balance sheet as total assets. All long-lived assets are maintained in the United States. The following table contains information on segment profit or loss, including significant segment expenses (in thousands):

	YEAR ENDED DECEMBER 31,
	2024			2023
Revenue	$	251		$	33,492
Less:
AB-101		19,978			14,090
Other programs(a)		330			3,797
Personnel-related		30,465			28,610
Other(b)		16,760			17,666
Other income, net		1,909			2,023
Provision for income taxes		—			(72	)
Net loss	$	(65,373	)	$	(28,720	)

(a)Other programs primarily includes costs associated with AB-201, Merck, and Affimed.

(b)Other primarily includes consultant, depreciation, rent, common area maintenance, lab supplies, legal, and insurance expenses.